Back to top

Image: Bigstock

BioNTech (BNTX) Looks Good: Stock Adds 5.9% in Session

Read MoreHide Full Article

BioNTech SE (BNTX - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 32.9% in the past one-month time frame.

The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for BioNTech. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

BioNTech currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.

Another stock worth considering in the Medical - Biomedical and Genetics industry is Akcea Therapeutics Inc (AKCA - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Akcea Therapeutics, Inc. (AKCA) - free report >>

BioNTech SE Sponsored ADR (BNTX) - free report >>